Establishment of a novel in vivo model of human leukemia

新型人白血病体内模型的建立

基本信息

  • 批准号:
    17500290
  • 负责人:
  • 金额:
    $ 2.3万
  • 依托单位:
  • 依托单位国家:
    日本
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
  • 财政年份:
    2005
  • 资助国家:
    日本
  • 起止时间:
    2005 至 2006
  • 项目状态:
    已结题

项目摘要

It has been demonstrated that leukemic stem cells have extensive self-renewal potential and their hierarchical organization of stem cell pool was notably similar to the normal hematopoietic stem cell (HSC) compartment. These findings propose the idea that some forms of leukemia imitate a system of the normal long-term HSC and retain or acquire the extensive self-renewal capacity. However, the precise characteristics regarding the multipotency of human HSC remains elusive. To elucidate the multipotency of human HSCs, CD34^+CD38^- cells were infected with lentivirus vector and transplanted into immunodeficient mice. We analyzed the multilineage differentiation and self-renewal abilities of individual thymus-repopulating clones in primary recipients, and their descending clones paired secondary recipients, by tracing lentivirus gene integration sites in each lymphomyeloid progeny using a linear amplification-mediated PCR strategy. Our clonal analysis revealed that a single human thymus-re … More populating cell had the ability to produce lymphoid and myeloid lineage cells in primary recipient and each secondary recipient, indicating that individual human HSCs expand clonally by self-renewal division. Furthermore, we found that the proportion of HSC clones present in the CD34^+ cell population decreased as HSCs replicated during extensive repopulation and also as the differentiation capacity of the HSC clones became limited. This indicates the restriction of the ability of individual HSCs despite the expansion of total HSC population. We also demonstrated that the extensive self-renewal potential was confined in the relatively small proportion of HSC clones. We conclude that our clonal tracking studies clearly demonstrated that heterogeneity in the self-renewal capacity of HSC clones underlies the differences in clonal longevity in the CD34^+ stem cell pool. The clonal analysis for properties of long-term HSCs in vivo would be a powerful tool to understand the mechanisms for tumor initiation, progression and relapses, and lead to efficient utilization of HSCs in clinical transplantation medicine. Less
已经证明,白血病干细胞具有广泛的自我更新潜力,与正常的造血干细胞(HSC)相似的LY结构组织。 f人类HSC的广泛更新能力仍然难以捉摸。他们的下降克隆使用线性扩增的PCR策略配对二级受体,我们的克隆分析是一个人的胸腺。次级接受者,表明单个HSC通过自我更新分裂在克隆中扩展,我们发现CD34^+细胞种群中HSC克隆的建议随着HSC在广泛的tion中的复制而降低,并且随着HSC克隆的扩散性也受到限制。 HSC总体的扩展。 - 体内的HSC会使肿瘤起步,进展和复发,并导致HSC在临床移植医学中的效率

项目成果

期刊论文数量(11)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Clonal analysis of thymus-repopulating cells presents direct evidence for self-renewal division of human hematopoietic stem cells.
胸腺再生细胞的克隆分析为人类造血干细胞的自我更新分裂提供了直接证据。
  • DOI:
  • 发表时间:
    2006
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Yahata;T
  • 通讯作者:
    T
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

YAHATA Takashi其他文献

YAHATA Takashi的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('YAHATA Takashi', 18)}}的其他基金

Blockade of PAI-1 eliminates leukemic stem cells
阻断 PAI-1 可消除白血病干细胞
  • 批准号:
    15H04301
  • 财政年份:
    2015
  • 资助金额:
    $ 2.3万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Establishment of hematopoietic regeneration by the novel molecular targeting drug
新型分子靶向药物建立造血再生
  • 批准号:
    24590361
  • 财政年份:
    2012
  • 资助金额:
    $ 2.3万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
DNA damage response in human hematopoietic stem cell
人类造血干细胞的DNA损伤反应
  • 批准号:
    22790299
  • 财政年份:
    2010
  • 资助金额:
    $ 2.3万
  • 项目类别:
    Grant-in-Aid for Young Scientists (B)
Analysis of repopulating dynamics of human hematopoietic stem cells
人类造血干细胞的增殖动态分析
  • 批准号:
    20790238
  • 财政年份:
    2008
  • 资助金额:
    $ 2.3万
  • 项目类别:
    Grant-in-Aid for Young Scientists (B)
Establishment of human hematopoietic system model mouse for understanding the regulatory mechanisms of human hematopoiesis.
建立人类造血系统模型小鼠,以了解人类造血的调控机制。
  • 批准号:
    18500332
  • 财政年份:
    2006
  • 资助金额:
    $ 2.3万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)

相似国自然基金

Gremlin1阳性骨髓微环境细胞在调控造血干细胞干性、抑制髓系白血病进展中的作用和机制研究
  • 批准号:
  • 批准年份:
    2022
  • 资助金额:
    30 万元
  • 项目类别:
    青年科学基金项目
血管内皮细胞促进NK细胞教育降低造血干细胞移植后白血病复发的机制研究
  • 批准号:
  • 批准年份:
    2022
  • 资助金额:
    52 万元
  • 项目类别:
    面上项目
分子伴侣介导的自噬在白血病前体造血干细胞形成中的调控作用和机制研究
  • 批准号:
  • 批准年份:
    2022
  • 资助金额:
    52 万元
  • 项目类别:
    面上项目
SETD5在造血干细胞调控及白血病发生发展中的作用及机制研究
  • 批准号:
  • 批准年份:
    2021
  • 资助金额:
    55 万元
  • 项目类别:
    面上项目
IL-4信号通路参与急性髓系白血病下巨核-血小板生成障碍及机制研究
  • 批准号:
    81900109
  • 批准年份:
    2019
  • 资助金额:
    20.0 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

Investigating hematopoietic stem cell dysfunction during sickle cell disease
研究镰状细胞病期间的造血干细胞功能障碍
  • 批准号:
    10681829
  • 财政年份:
    2023
  • 资助金额:
    $ 2.3万
  • 项目类别:
Fast-kinetics approaches to define direct gene-regulatory functions of MYB in leukemia
快速动力学方法定义 MYB 在白血病中的直接基因调控功能
  • 批准号:
    10644259
  • 财政年份:
    2023
  • 资助金额:
    $ 2.3万
  • 项目类别:
Mechanisms of Parp inhibitor-induced bone marrow toxicities
Parp 抑制剂诱导骨髓毒性的机制
  • 批准号:
    10637962
  • 财政年份:
    2023
  • 资助金额:
    $ 2.3万
  • 项目类别:
Cancer Therapeutics and Host Response Research Program
癌症治疗和宿主反应研究计划
  • 批准号:
    10625756
  • 财政年份:
    2023
  • 资助金额:
    $ 2.3万
  • 项目类别:
Phase 2 clinical trial of a novel T cell therapy following bridging therapy with hypomethylating agents for relapsed AML patients post-stem cell transplant
干细胞移植后复发性 AML 患者使用低甲基化药物桥接治疗后新型 T 细胞疗法的 2 期临床试验
  • 批准号:
    10761513
  • 财政年份:
    2023
  • 资助金额:
    $ 2.3万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了